CGT Drug Developer Pregene Receives Acceptance of IPO Advisory Filing
Pregene
Cell Therapy Drug Developer
April 21, 2024
eMedClub News
▲ Announcement of Companies Listed on the New Third Board
PregeneIt is a national high-tech enterprise, the Guangdong Provincial Cell and Gene Therapy Innovative Drug Engineering Technology Research Center, and a Shenzhen-based specialized and innovative enterprise. Its investors include the National Small and Medium Enterprise Development Fund, Guoke Jiahe Fund under the Chinese Academy of Sciences, Haier Capital, Shenzhen Capital Group, Huabang Health, etc.
PregeneAfter years of in-depth development in the cell and gene therapy (CGT) drug field, the product pipeline includes CAR-T, CAR-NK drugs targeting multiple sites, with indications covering various therapeutic areas such as hematologic tumors, solid tumors, and autoimmune diseases.
In 2020, Pregene completed a 140 million RMB Series B financing round, led by Haier Healthcare with participation from Huabang Health, Hunan Health and Elderly Care Industry Investment Fund, and Guoke Jiahé. On July 12, 2023, Pregene (874090) was listed on the NEEQ.
Hot Topic
Progress in the Clinical Development of NK Cell Therapy
Original Opportunities and Challenges of Cell Therapy Drugs
Development Strategies for iPSC-Derived NK Cell Therapy in Tumor Treatment
Exploration of Payment Methods for CAR-T Cell Therapy
Market Opportunities and Challenges for TIL Therapy
Research Progress of CAR-NK Cell Therapy in the Treatment of Hematological Tumors
Development Strategies for CAR-T Cell Therapy Targeting Glioblastoma
Development and Challenges of CAR-T Cell Therapy Derived from Cord Blood
Clinical Exploration of CLDN18.2-Targeted CAR-T in Solid Tumors
Application of mRNA Technology in CAR Cell Therapy
Progress in TCR-T Cell Therapy for Solid Tumors
Development Strategies for CAR-M Cell Therapy
Roundtable: Feasibility Discussion on the Global Cell Drug Commercialization Entering an Explosive Growth Phase
Roundtable: Technological Innovation Opportunities in Tumor Immunocyte Therapy
Scan the code
Limited Time Offer
Free Tickets
Hotline for Cooperation
18701871600 (Manager Wang)
15572286596 (Manager Yuan)
15221150919 (Manager He)
Pregene adheres to the development strategy and path of technologization, platform productization, product commercialization, and business internationalization. It is currently a leading innovative cell drug company in the industry that has achieved multi-regional global licensing for CAR-T cell drugs.After years of investment and development, Pregene has established a complete R&D and production quality management system for cell-based drugs. It has successfully built an innovative and industrialized core technology platform for nanobody screening, immune cell drug discovery, plasmid/viral vector process development and production, and cell process development and production, and has passed the ISO9001 quality management system certification.
Dr. Zhang Jishuai, founder of Pregene, pointed out that cell drugs represent a completely new generation of pharmaceutical technology, and their revolutionary significance lies in extending patients' lives.
BCMA is a new target for CAR-T drugs and an ideal target for myeloma immunotherapy. Notably, the market potential for BCMA-targeted CAR-T products is approximately $20 billion, and Pregene has already...In-depth in this fieldLayout。
According to the 21st Century Business Herald, PRG1801, a BCMA-targeted CAR-T cell drug developed by Pregene for the treatment of relapsed and refractory multiple myeloma, is the fastest-progressing cell drug globally using chimeric humanized nanobodies. It was approved by China's Center for Drug Evaluation in March 2020 and has now entered Phase II clinical trials.
PRG1801 Shows Significant Efficacy and Good Safety. According to follow-up data from 34 patients who received PRG1801, the ORR (Objective Response Rate) was as high as 88%, and the 18-month OS (Overall Survival) was 76.5%. In the registrational clinical trial, the ORR among 15 treated subjects reached 100%. More importantly, although CAR-T therapy is associated with relatively higher neurotoxicity and AE mortality rates, no significant safety issues were observed during the follow-up of PRG1801.
Live Broadcast Preview
On April 25, Advancements in the Application of Cutting-edge Cell Analysis Technology Accelerate Innovation in Drug Development and Immunotherapy Research
DianDian "Share”、“Like" and "In View", charge me up a bit~"